-
Ranjana Advani, MD; Stanford University #BtC_ASCO21
15:14
Dr. Ranjana Advani shares strategies for Integrating Recently Approved Therapies for B-cell NHL Into Practice.
-
Gail Roboz, MD; Weill Cornell Medicine #BtC_ASCO21
12:35
Dr. Gail Roboz presents on Personalizing Therapy for Adult Patients with ALL.
-
Selina Luger, MD, FRCPC; University of Pennsylvania #BtC_ASCO21
18:13
Dr. Selina Luger discusses Biomarkers and their Implications for Therapy in AML.
-
Alison J. Moskowitz, MD; Memorial Sloan Kettering Cancer Center #BtC_ASCO21
16:28
Dr. Alison Moskowitz presents on Treatments for Upfront and Relapsed Hodgkin’s Lymphoma.
-
Jennifer R. Brown, MD, PhD; Dana-Farber Cancer Institute #BtC_ASCO21
15:33
Dr. Jennifer Brown reviews Recently Presented Data of Clinical Trials and Standard of Care in Relapsed/Refractory CLL.
-
Maria-Victoria Mateos, MD, PhD; University of Salamanca #BtC_ASCO21
13:10
Dr. Maria-Victoria Mateos discusses Recently Presented Data of Clinical Trials and Standard of Care in Relapsed/Refractory MM
-
John P. Leonard, MD; Weill Cornell Medicine #BtC_ASCO21
16:48
Dr. John Leonard discusses Recently Presented Data of Clinical Trials in Patients with NHL.
-
Sagar Lonial, MD, FACP; Emory University #BtC_ASCO21
14:48
Dr. Sagar Lonial reviews Recently Presented Data of Clinical Trials and Standard of Care in Upfront Treatment for MM
-
Nicole Lamanna, MD; Columbia University #BtC_ASCO21
16:56
Dr. Nicole Lamanna discusses Practical Issues in Treating CLL: Sequencing, Oral Adherence, Managing Adverse Events, and MRD Analysis.
-
Naveen Pemmaraju, MD; MD Anderson Cancer Center #BtC_ASCO21
14:58
Dr. Naveen Pemmaraju discusses Using and Sequencing JAK Inhibitors for Patients with Myelofibrosis.
-
Matthew Davids, MD, MMSc; Dana-Farber Cancer Inst. #BtC_ASCO21
15:27
Dr. Matthew Davids reviews Recently Presented Data of Clinical Trials and Standard of Care in Upfront Treatment for CLL.
- Next Page